Table 4.
Association between CBC and long-term outcomes after RP among black and white men
| All | Black men | White men | ||||
|---|---|---|---|---|---|---|
| HR (99% CI) | p-value | HR (99% CI) | p-value | HR (99% CI) | p-value | |
| CRPC | ||||||
| Neutrophils | 0.94 (0.72–1.24) | 0.59 | 0.88 (0.57–1.36) | 0.44 | 1.00 (0.69–1.45) | 0.99 |
| Lymphocytes | 1.11 (0.61–2.01) | 0.65 | 0.93 (0.38–2.26) | 0.83 | 1.31 (0.58–2.95) | 0.39 |
| Platelets | 1.03 (0.96–1.10) | 0.28 | 1.01 (0.91–1.12) | 0.74 | 1.04 (0.96–1.13) | 0.24 |
| NLR | 0.96 (0.68–1.37) | 0.79 | 1.01 (0.59–1.72) | 0.97 | 0.93 (0.57–1.53) | 0.72 |
| PLR | 1.00 (0.99–1.01) | 0.95 | 1.00 (0.99–1.01) | 0.97 | 1.00 (0.99–1.01) | 0.96 |
| Metastases | ||||||
| Neutrophils | 1.00 (0.82–1.22) | 0.99 | 0.97 (0.71–1.32) | 0.79 | 1.07 (0.80–1.43) | 0.53 |
| Lymphocytes | 1.18 (0.74–1.86) | 0.37 | 0.90 (0.46–1.78) | 0.70 | 1.50 (0.79–2.84) | 0.11 |
| Platelets | 1.02 (0.97–1.08) | 0.19 | 1.00 (0.92–1.08) | 0.99 | 1.04 (0.98–1.12) | 0.076 |
| NLR | 1.01 (0.78–1.32) | 0.92 | 1.10 (0.76–1.58) | 0.51 | 0.98 (0.66–1.44) | 0.88 |
| PLR | 1.00 (0.99–1.00) | 0.60 | 1.00 (0.99–1.01) | 0.83 | 1.00 (0.99–1.00) | 0.63 |
| ACM* | ||||||
| Neutrophils | 1.08 (0.98–1.19) | 0.048 | 1.00 (0.86–1.16) | 0.99 | 1.16 (1.01–1.33) | 0.004 |
| Lymphocytes | 1.02 (0.80–1.28) | 0.85 | 1.01 (0.73–1.39) | 0.95 | 1.07 (0.75–1.51) | 0.63 |
| Platelets | 1.01 (0.98–1.03) | 0.61 | 1.01 (0.97–1.06) | 0.43 | 1.00 (0.96–1.04) | 0.97 |
| NLR | 1.04 (0.91–1.17) | 0.42 | 0.95 (0.79–1.16) | 0.52 | 1.14 (0.96–1.34) | 0.047 |
| PLR | 1.00 (1.00–1.00) | 0.33 | 1.00 (1.00–1.01) | 0.42 | 1.00 (1.00–1.00) | 0.64 |
| PCSM | ||||||
| Neutrophils | 1.07 (0.79–1.46) | 0.57 | 0.88 (0.51–1.54) | 0.56 | 1.17 (0.79–1.74) | 0.30 |
| Lymphocytes | 1.17 (0.59–2.31) | 0.56 | 1.07 (0.37–3.11) | 0.86 | 1.29 (0.52–3.20) | 0.47 |
| Platelets | 1.05 (0.97–1.13) | 0.11 | 1.02 (0.90–1.16) | 0.67 | 1.06 (0.97–1.16) | 0.093 |
| NLR | 1.15 (0.81–1.65) | 0.30 | 1.07 (0.57–1.99) | 0.78 | 1.19 (0.74–1.92) | 0.34 |
| PLR | 1.00 (0.99–1.01) | 0.98 | 1.00 (0.98–1.01) | 0.90 | 1.00 (0.99–1.01) | 0.96 |
There were 47 CRPC, 76 metastases, 329 all-cause deaths, and 35 prostate cancer-specific deaths
*
Adjusted for VA center and clinical and pathological characteristics: age, PSA, year of surgery, pathological Gleason score, positive margins, extracapsular extension, seminal vesicles and lymph node involvement
CRPC=castration-resistant prostate cancer; NLR= neutrophil-lymphocyte ratio; PLR= platelet-lymphocyte ratio; ACM=all-cause mortality; PCSM=prostate cancer-specific mortality; HR=hazard ratio